{"transactions":[{"id":3081941,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":125861,"kind":"organization","name":"NOVARTIS PHARMA AG","position":1,"cik":"0001030617","reported_name":"NOVARTIS PHARMA AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-07-16T16:53:14.000Z","date":"2020-07-14","kind":"exercise","acquired":false,"shares":7367387,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5908089},"source":{"system":"sec-edgar","filing":"0001104659-20-084106","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1030617/000110465920084106/a4.xml","form_type":"4"}},{"id":3081940,"issuer":{"id":84243,"kind":"organization","name":"Poseida Therapeutics, Inc.","symbol":"PSTX"},"owners":[{"id":125861,"kind":"organization","name":"NOVARTIS PHARMA AG","position":1,"cik":"0001030617","reported_name":"NOVARTIS PHARMA AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-16T16:53:14.000Z","date":"2020-07-14","kind":"exercise","acquired":true,"shares":5908089,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series C Preferred Stock automatically converted into 0.8019246 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is an indirect beneficial owner of these securities."}],"balance_after":5908089,"source":{"system":"sec-edgar","filing":"0001104659-20-084106","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1030617/000110465920084106/a4.xml","form_type":"4"}},{"id":3092651,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series B Preferred Stock","published_at":"2020-07-02T20:16:29.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":199996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":199996},"source":{"system":"sec-edgar","filing":"0001104659-20-080559","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465920080559/a4.xml","form_type":"4"}},{"id":3092650,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series A Preferred Stock","published_at":"2020-07-02T20:16:29.000Z","date":"2020-06-30","kind":"exercise","acquired":false,"shares":856262,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":856262},"source":{"system":"sec-edgar","filing":"0001104659-20-080559","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465920080559/a4.xml","form_type":"4"}},{"id":3092649,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-07-02T20:16:29.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":125000,"price":17,"value":2125000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":1181258,"source":{"system":"sec-edgar","filing":"0001104659-20-080559","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465920080559/a4.xml","form_type":"4"}},{"id":3092648,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-07-02T20:16:29.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":199996,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On June 30, 2020, the Series B Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":1056258,"source":{"system":"sec-edgar","filing":"0001104659-20-080559","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465920080559/a4.xml","form_type":"4"}},{"id":3092647,"issuer":{"id":11574,"kind":"organization","name":"Akouos, Inc.","symbol":"AKUS"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-07-02T20:16:29.000Z","date":"2020-06-30","kind":"exercise","acquired":true,"shares":856262,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 30, 2020, the Series A Preferred Stock converted into Common Stock on a 21.073-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":856262,"source":{"system":"sec-edgar","filing":"0001104659-20-080559","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465920080559/a4.xml","form_type":"4"}},{"id":3103359,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-06-22T20:52:19.000Z","date":"2020-06-19","kind":"sale","acquired":false,"shares":1001312,"price":8.25,"value":8260824.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $8.25 to $9.17. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":2467961,"source":{"system":"sec-edgar","filing":"0000925421-20-000256","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000256/edgar.xml","form_type":"4"}},{"id":3103358,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2020-06-22T20:52:19.000Z","date":"2020-06-18","kind":"sale","acquired":false,"shares":900,"price":9.04,"value":8136.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.37. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3469273,"source":{"system":"sec-edgar","filing":"0000925421-20-000256","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000256/edgar.xml","form_type":"4"}},{"id":3107468,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-17T21:47:16.000Z","date":"2020-06-17","kind":"sale","acquired":false,"shares":4622,"price":9.27,"value":42845.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.25 to $9.32. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3470173,"source":{"system":"sec-edgar","filing":"0000925421-20-000254","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000254/edgar.xml","form_type":"4"}},{"id":3107467,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-17T21:47:16.000Z","date":"2020-06-16","kind":"sale","acquired":false,"shares":8600,"price":9.3,"value":79980.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.07 to $9.37. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3474795,"source":{"system":"sec-edgar","filing":"0000925421-20-000254","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000254/edgar.xml","form_type":"4"}},{"id":3107466,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-17T21:47:16.000Z","date":"2020-06-15","kind":"sale","acquired":false,"shares":6164,"price":9.05,"value":55784.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.10. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3483395,"source":{"system":"sec-edgar","filing":"0000925421-20-000254","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000254/edgar.xml","form_type":"4"}},{"id":3112153,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T22:33:27.000Z","date":"2020-06-12","kind":"sale","acquired":false,"shares":1500,"price":9.19,"value":13785.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.38. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3489559,"source":{"system":"sec-edgar","filing":"0000925421-20-000248","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000248/edgar.xml","form_type":"4"}},{"id":3112152,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T22:33:27.000Z","date":"2020-06-11","kind":"sale","acquired":false,"shares":7200,"price":9.21,"value":66312.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.39. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3491059,"source":{"system":"sec-edgar","filing":"0000925421-20-000248","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000248/edgar.xml","form_type":"4"}},{"id":3112151,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-12T22:33:27.000Z","date":"2020-06-10","kind":"sale","acquired":false,"shares":8532,"price":9.46,"value":80712.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.19 to $9.74. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3498259,"source":{"system":"sec-edgar","filing":"0000925421-20-000248","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000248/edgar.xml","form_type":"4"}},{"id":3116990,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-10T00:02:01.000Z","date":"2020-06-09","kind":"sale","acquired":false,"shares":7000,"price":9.38,"value":65660.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.30 to $9.56. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3506791,"source":{"system":"sec-edgar","filing":"0000925421-20-000244","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000244/edgar.xml","form_type":"4"}},{"id":3116989,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-10T00:02:01.000Z","date":"2020-06-08","kind":"sale","acquired":false,"shares":5659,"price":9.66,"value":54665.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.50 to $9.83. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3513791,"source":{"system":"sec-edgar","filing":"0000925421-20-000244","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000244/edgar.xml","form_type":"4"}},{"id":3116988,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-10T00:02:01.000Z","date":"2020-06-05","kind":"sale","acquired":false,"shares":8652,"price":9.66,"value":83578.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.35 to $9.89. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3519450,"source":{"system":"sec-edgar","filing":"0000925421-20-000244","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000244/edgar.xml","form_type":"4"}},{"id":3122371,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T21:36:30.000Z","date":"2020-06-04","kind":"sale","acquired":false,"shares":4088,"price":9.55,"value":39040.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.36 to $9.84. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3528102,"source":{"system":"sec-edgar","filing":"0000925421-20-000228","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000228/edgar.xml","form_type":"4"}},{"id":3122370,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T21:36:30.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":5208,"price":9.78,"value":50934.24,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.68 to $10.00. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3532190,"source":{"system":"sec-edgar","filing":"0000925421-20-000228","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000228/edgar.xml","form_type":"4"}},{"id":3122369,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T21:36:30.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":5669,"price":9.68,"value":54875.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $9.50 to $9.90. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3537398,"source":{"system":"sec-edgar","filing":"0000925421-20-000228","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542120000228/edgar.xml","form_type":"4"}},{"id":3374910,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2019-11-12T21:15:33.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":451609,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":89311},"source":{"system":"sec-edgar","filing":"0000899243-19-027115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000089924319027115/doc4.xml","form_type":"4"}},{"id":3374909,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-11-12T21:15:33.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":7200000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1423891},"source":{"system":"sec-edgar","filing":"0000899243-19-027115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000089924319027115/doc4.xml","form_type":"4"}},{"id":3374908,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2019-11-12T21:15:33.000Z","date":"2019-11-12","kind":"exercise","acquired":false,"shares":9000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1779864},"source":{"system":"sec-edgar","filing":"0000899243-19-027115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000089924319027115/doc4.xml","form_type":"4"}},{"id":3374907,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T21:15:33.000Z","date":"2019-11-12","kind":"purchase","acquired":true,"shares":250000,"price":12,"value":3000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3543067,"source":{"system":"sec-edgar","filing":"0000899243-19-027115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000089924319027115/doc4.xml","form_type":"4"}},{"id":3374906,"issuer":{"id":15899,"kind":"organization","name":"Galera Therapeutics, Inc.","symbol":"GRTX"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-11-12T21:15:33.000Z","date":"2019-11-12","kind":"exercise","acquired":true,"shares":3293067,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a 0.197763-for-one basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Novartis Bioventures Ltd. Is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities."}],"balance_after":3293067,"source":{"system":"sec-edgar","filing":"0000899243-19-027115","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000089924319027115/doc4.xml","form_type":"4"}},{"id":3507717,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B1 Preferred Shares","published_at":"2019-05-31T01:27:55.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":636366,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":636366},"source":{"system":"sec-edgar","filing":"0001104659-19-032920","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465919032920/a4.xml","form_type":"4"}},{"id":3507716,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares Warrants","published_at":"2019-05-31T01:27:55.000Z","date":"2019-05-28","kind":"other","acquired":false,"shares":71450,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the  Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":71450},"source":{"system":"sec-edgar","filing":"0001104659-19-032920","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465919032920/a4.xml","form_type":"4"}},{"id":3507715,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Shares","published_at":"2019-05-31T01:27:55.000Z","date":"2019-05-28","kind":"exercise","acquired":false,"shares":893195,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":893195},"source":{"system":"sec-edgar","filing":"0001104659-19-032920","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465919032920/a4.xml","form_type":"4"}},{"id":3507714,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-31T01:27:55.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":168630,"price":14,"value":2360820.0,"ownership":{"direct":true},"balance_after":1769641,"source":{"system":"sec-edgar","filing":"0001104659-19-032920","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465919032920/a4.xml","form_type":"4"}},{"id":3507713,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-31T01:27:55.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":636366,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":1601011,"source":{"system":"sec-edgar","filing":"0001104659-19-032920","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465919032920/a4.xml","form_type":"4"}},{"id":3507712,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-31T01:27:55.000Z","date":"2019-05-28","kind":"other","acquired":true,"shares":71450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":964645,"source":{"system":"sec-edgar","filing":"0001104659-19-032920","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465919032920/a4.xml","form_type":"4"}},{"id":3507711,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2019-05-31T01:27:55.000Z","date":"2019-05-28","kind":"exercise","acquired":true,"shares":893195,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date."}],"balance_after":893195,"source":{"system":"sec-edgar","filing":"0001104659-19-032920","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465919032920/a4.xml","form_type":"4"}},{"id":3546756,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-29T21:23:36.000Z","date":"2019-04-26","kind":"sale","acquired":false,"shares":138704,"price":1.03,"value":142865.12,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.02 to $1.05. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4049804,"source":{"system":"sec-edgar","filing":"0000925421-19-000179","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000179/edgar.xml","form_type":"4"}},{"id":3546755,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-29T21:23:36.000Z","date":"2019-04-25","kind":"sale","acquired":false,"shares":563096,"price":1.03,"value":579988.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.00 to $1.04. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4188508,"source":{"system":"sec-edgar","filing":"0000925421-19-000179","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000179/edgar.xml","form_type":"4"}},{"id":3550373,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T23:03:35.000Z","date":"2019-04-24","kind":"sale","acquired":false,"shares":16403,"price":1.03,"value":16895.09,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.03 to $1.06. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4751604,"source":{"system":"sec-edgar","filing":"0000925421-19-000157","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000157/edgar.xml","form_type":"4"}},{"id":3550372,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T23:03:35.000Z","date":"2019-04-23","kind":"sale","acquired":false,"shares":27554,"price":1.03,"value":28380.62,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.99 to $1.06. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4768007,"source":{"system":"sec-edgar","filing":"0000925421-19-000157","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000157/edgar.xml","form_type":"4"}},{"id":3550371,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-24T23:03:35.000Z","date":"2019-04-22","kind":"sale","acquired":false,"shares":7100,"price":0.97,"value":6887.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.95 to $0.99. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4795561,"source":{"system":"sec-edgar","filing":"0000925421-19-000157","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000157/edgar.xml","form_type":"4"}},{"id":3556086,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-16T01:26:50.000Z","date":"2019-04-15","kind":"sale","acquired":false,"shares":28794,"price":0.99,"value":28506.06,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.97 to $1.03. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4802661,"source":{"system":"sec-edgar","filing":"0000925421-19-000153","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000153/edgar.xml","form_type":"4"}},{"id":3556085,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-16T01:26:50.000Z","date":"2019-04-12","kind":"sale","acquired":false,"shares":30908,"price":1.04,"value":32144.32,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.02 to $1.08. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4831455,"source":{"system":"sec-edgar","filing":"0000925421-19-000153","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000153/edgar.xml","form_type":"4"}},{"id":3556084,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-16T01:26:50.000Z","date":"2019-04-11","kind":"sale","acquired":false,"shares":57438,"price":1.08,"value":62033.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.03 to $1.15. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4862363,"source":{"system":"sec-edgar","filing":"0000925421-19-000153","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000153/edgar.xml","form_type":"4"}},{"id":3558624,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T22:26:02.000Z","date":"2019-04-10","kind":"sale","acquired":false,"shares":140230,"price":1.09,"value":152850.7,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.02 to $1.15. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":4919801,"source":{"system":"sec-edgar","filing":"0000925421-19-000149","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000149/edgar.xml","form_type":"4"}},{"id":3558623,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T22:26:02.000Z","date":"2019-04-09","kind":"sale","acquired":false,"shares":32991,"price":1.01,"value":33320.91,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.98 to $1.03. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":5060031,"source":{"system":"sec-edgar","filing":"0000925421-19-000149","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000149/edgar.xml","form_type":"4"}},{"id":3558622,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-10T22:26:02.000Z","date":"2019-04-08","kind":"sale","acquired":false,"shares":27525,"price":1.02,"value":28075.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.00 to $1.08. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":5093022,"source":{"system":"sec-edgar","filing":"0000925421-19-000149","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000149/edgar.xml","form_type":"4"}},{"id":3561804,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-05T21:14:00.000Z","date":"2019-04-05","kind":"sale","acquired":false,"shares":24661,"price":1.02,"value":25154.22,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.99 to $1.05. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":5120547,"source":{"system":"sec-edgar","filing":"0000925421-19-000145","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000145/edgar.xml","form_type":"4"}},{"id":3561803,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-05T21:14:00.000Z","date":"2019-04-04","kind":"sale","acquired":false,"shares":47900,"price":1.01,"value":48379.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.98 to $1.02. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":5145208,"source":{"system":"sec-edgar","filing":"0000925421-19-000145","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000145/edgar.xml","form_type":"4"}},{"id":3561802,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-05T21:14:00.000Z","date":"2019-04-03","kind":"sale","acquired":false,"shares":58033,"price":0.96,"value":55711.68,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.93 to $1.01. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":5193108,"source":{"system":"sec-edgar","filing":"0000925421-19-000145","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000145/edgar.xml","form_type":"4"}},{"id":3569397,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T00:23:51.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":20610,"price":1.9,"value":39159.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.81 to $2.02. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2079394,"source":{"system":"sec-edgar","filing":"0000925421-19-000143","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000143/edgar.xml","form_type":"4"}},{"id":3569396,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T00:23:51.000Z","date":"2019-03-29","kind":"sale","acquired":false,"shares":106540,"price":1.85,"value":197099.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.76 to $1.96. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2100004,"source":{"system":"sec-edgar","filing":"0000925421-19-000143","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000143/edgar.xml","form_type":"4"}},{"id":3569395,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T00:09:59.000Z","date":"2019-04-02","kind":"sale","acquired":false,"shares":51754,"price":0.97,"value":50201.38,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.93 to $1.00. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":5251141,"source":{"system":"sec-edgar","filing":"0000925421-19-000141","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000141/edgar.xml","form_type":"4"}},{"id":3569394,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T00:09:59.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":116909,"price":0.95,"value":111063.55,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.90 to $0.99. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":5302895,"source":{"system":"sec-edgar","filing":"0000925421-19-000141","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000141/edgar.xml","form_type":"4"}},{"id":3569393,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-04-03T00:09:59.000Z","date":"2019-03-29","kind":"sale","acquired":false,"shares":63100,"price":0.91,"value":57421.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.88 to $0.96. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":5419804,"source":{"system":"sec-edgar","filing":"0000925421-19-000141","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000141/edgar.xml","form_type":"4"}},{"id":3575705,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-28T21:16:20.000Z","date":"2019-03-28","kind":"sale","acquired":false,"shares":88835,"price":0.94,"value":83504.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.92 to $1.00. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":5482904,"source":{"system":"sec-edgar","filing":"0000925421-19-000139","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000139/edgar.xml","form_type":"4"}},{"id":3575704,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-28T21:16:20.000Z","date":"2019-03-27","kind":"sale","acquired":false,"shares":50749,"price":0.99,"value":50241.51,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $0.99 to $1.02. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":5571739,"source":{"system":"sec-edgar","filing":"0000925421-19-000139","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000139/edgar.xml","form_type":"4"}},{"id":3575703,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-28T21:16:20.000Z","date":"2019-03-26","kind":"sale","acquired":false,"shares":177762,"price":1.01,"value":179539.62,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.00 to $1.06. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":5622488,"source":{"system":"sec-edgar","filing":"0000925421-19-000139","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000139/edgar.xml","form_type":"4"}},{"id":3593764,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-15T21:25:56.000Z","date":"2019-03-15","kind":"sale","acquired":false,"shares":43800,"price":1.92,"value":84096.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.85 to $2.02. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2206544,"source":{"system":"sec-edgar","filing":"0000925421-19-000114","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000114/edgar.xml","form_type":"4"}},{"id":3593763,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-15T21:25:56.000Z","date":"2019-03-14","kind":"sale","acquired":false,"shares":13800,"price":1.88,"value":25944.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $1.85 to $1.915. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2250344,"source":{"system":"sec-edgar","filing":"0000925421-19-000114","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000114/edgar.xml","form_type":"4"}},{"id":3593762,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-03-15T21:25:56.000Z","date":"2019-03-13","kind":"sale","acquired":false,"shares":132738,"price":2.12,"value":281404.56,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.00 to $2.42. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2264144,"source":{"system":"sec-edgar","filing":"0000925421-19-000114","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000114/edgar.xml","form_type":"4"}},{"id":3657230,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T21:02:21.000Z","date":"2018-07-16","kind":"other","acquired":true,"shares":25074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\") is a limited partner."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG."}],"balance_after":4352295,"source":{"system":"sec-edgar","filing":"0000925421-19-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000049/edgar.xml","form_type":"5"}},{"id":3657229,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T21:02:21.000Z","date":"2018-06-18","kind":"other","acquired":true,"shares":25074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\") is a limited partner."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG."}],"balance_after":4327221,"source":{"system":"sec-edgar","filing":"0000925421-19-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000049/edgar.xml","form_type":"5"}},{"id":3657228,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-02-14T21:02:21.000Z","date":"2018-05-16","kind":"other","acquired":true,"shares":25074,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\") is a limited partner."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG."}],"balance_after":4302147,"source":{"system":"sec-edgar","filing":"0000925421-19-000049","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542119000049/edgar.xml","form_type":"5"}},{"id":3815968,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2018-09-14T13:14:00.000Z","date":"2018-09-12","kind":"other","acquired":false,"shares":465086,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Exchange Agreement between the Issuer and the Reporting Persons dated July 11, 2018, the remaining warrants to purchase the Issuer's common stock (the \"Warrants\") were exchanged for shares of the Issuer's common stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Warrants to purchase shares of the Issuer's Common Stock were acquired in connection with the acquisition of the Preferred Stock and reported on this Form 4. The Warrants held by Novartis may not be exercised if such exercise would cause Novartis to hold more than 19.99% of the Issuer's Common Stock, regardless of receipt by the Issuer of the Requisite Stockholder Approval."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":0,"derivative":{"exercise_price":2.67,"exercise_date":"2017-08-21","expiration_date":"2022-08-21","underlying":"Common Stock, par value $0.0001","underlying_shares":465086},"source":{"system":"sec-edgar","filing":"0001012975-18-001065","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518001065/edgar.xml","form_type":"4"}},{"id":3815967,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2018-09-14T13:14:00.000Z","date":"2018-09-12","kind":"other","acquired":true,"shares":2069993,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Exchange Agreement between the Issuer and the Reporting Persons dated July 11, 2018, the remaining warrants to purchase the Issuer's common stock (the \"Warrants\") were exchanged for shares of the Issuer's common stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Exchange Agreement between the Issuer and the Reporting Persons dated July 11, 2018, the remaining warrants to purchase the Issuer's common stock (the \"Warrants\") were exchanged for shares of the Issuer's common stock, par value $0.0001 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":8345145,"source":{"system":"sec-edgar","filing":"0001012975-18-001065","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518001065/edgar.xml","form_type":"4"}},{"id":3836242,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-22T20:34:48.000Z","date":"2018-08-20","kind":"sale","acquired":false,"shares":20388,"price":2.3,"value":46892.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.06 to $2.53. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2396882,"source":{"system":"sec-edgar","filing":"0000925421-18-000300","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000300/edgar.xml","form_type":"4"}},{"id":3836235,"issuer":{"id":6074,"kind":"organization","name":"Whitehawk Therapeutics, Inc.","symbol":"WHWK"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-22T20:07:37.000Z","date":"2018-08-20","kind":"sale","acquired":false,"shares":5300,"price":3.9,"value":20670.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $3.90 to $3.91. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":5800250,"source":{"system":"sec-edgar","filing":"0000925421-18-000298","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000298/edgar.xml","form_type":"4"}},{"id":3838571,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-20T21:12:30.000Z","date":"2018-08-17","kind":"sale","acquired":false,"shares":8700,"price":2.1,"value":18270.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.02 to $2.18. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2417270,"source":{"system":"sec-edgar","filing":"0000925421-18-000294","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000294/edgar.xml","form_type":"4"}},{"id":3838570,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-20T21:12:30.000Z","date":"2018-08-16","kind":"sale","acquired":false,"shares":8808,"price":2.1,"value":18496.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.02 to $2.20. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2425970,"source":{"system":"sec-edgar","filing":"0000925421-18-000294","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000294/edgar.xml","form_type":"4"}},{"id":3842142,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-16T20:18:10.000Z","date":"2018-08-15","kind":"sale","acquired":false,"shares":2635,"price":2.15,"value":5665.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.13 to $2.25. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2434778,"source":{"system":"sec-edgar","filing":"0000925421-18-000292","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000292/edgar.xml","form_type":"4"}},{"id":3842141,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-16T20:18:10.000Z","date":"2018-08-14","kind":"sale","acquired":false,"shares":3300,"price":2.26,"value":7458.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.17 to $2.33. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2437413,"source":{"system":"sec-edgar","filing":"0000925421-18-000292","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000292/edgar.xml","form_type":"4"}},{"id":3845025,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-14T21:05:31.000Z","date":"2018-08-13","kind":"sale","acquired":false,"shares":1600,"price":2.36,"value":3776.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.32 to $2.40. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2440713,"source":{"system":"sec-edgar","filing":"0000925421-18-000290","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000290/edgar.xml","form_type":"4"}},{"id":3845024,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-14T21:05:31.000Z","date":"2018-08-10","kind":"sale","acquired":false,"shares":5615,"price":2.44,"value":13700.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.40 to $2.48. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2442313,"source":{"system":"sec-edgar","filing":"0000925421-18-000290","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000290/edgar.xml","form_type":"4"}},{"id":3847626,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-10T20:29:31.000Z","date":"2018-08-09","kind":"sale","acquired":false,"shares":235,"price":2.48,"value":582.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.47 to $2.50. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2447928,"source":{"system":"sec-edgar","filing":"0000925421-18-000284","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000284/edgar.xml","form_type":"4"}},{"id":3847625,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-10T20:29:31.000Z","date":"2018-08-08","kind":"sale","acquired":false,"shares":1000,"price":2.78,"value":2780.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.77 to $2.81. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2448163,"source":{"system":"sec-edgar","filing":"0000925421-18-000284","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000284/edgar.xml","form_type":"4"}},{"id":3849865,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-08T20:21:42.000Z","date":"2018-08-07","kind":"sale","acquired":false,"shares":1739,"price":2.97,"value":5164.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $2.95 to $2.98. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2449163,"source":{"system":"sec-edgar","filing":"0000925421-18-000282","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000282/edgar.xml","form_type":"4"}},{"id":3849864,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-08T20:21:42.000Z","date":"2018-08-06","kind":"sale","acquired":false,"shares":2942,"price":3.02,"value":8884.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $3.00 to $3.03. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2450902,"source":{"system":"sec-edgar","filing":"0000925421-18-000282","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000282/edgar.xml","form_type":"4"}},{"id":3852036,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-06T20:22:04.000Z","date":"2018-08-02","kind":"sale","acquired":false,"shares":4702,"price":3.33,"value":15657.66,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2453844,"source":{"system":"sec-edgar","filing":"0000925421-18-000278","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000278/edgar.xml","form_type":"4"}},{"id":3855260,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-02T20:33:31.000Z","date":"2018-08-01","kind":"sale","acquired":false,"shares":8181,"price":3.22,"value":26342.82,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $3.10 to $3.25. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2458546,"source":{"system":"sec-edgar","filing":"0000925421-18-000274","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000274/edgar.xml","form_type":"4"}},{"id":3855259,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-08-02T20:33:31.000Z","date":"2018-07-31","kind":"sale","acquired":false,"shares":4500,"price":3.07,"value":13815.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $3.08 to $3.14. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2466727,"source":{"system":"sec-edgar","filing":"0000925421-18-000274","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000274/edgar.xml","form_type":"4"}},{"id":3857999,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-31T20:16:46.000Z","date":"2018-07-30","kind":"sale","acquired":false,"shares":2000,"price":3.27,"value":6540.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $3.14 to $3.30. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2471227,"source":{"system":"sec-edgar","filing":"0000925421-18-000265","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000265/edgar.xml","form_type":"4"}},{"id":3857998,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-31T20:16:46.000Z","date":"2018-07-27","kind":"sale","acquired":false,"shares":6458,"price":3.38,"value":21828.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $3.36 to $3.50. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2473227,"source":{"system":"sec-edgar","filing":"0000925421-18-000265","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000265/edgar.xml","form_type":"4"}},{"id":3860139,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-27T20:21:45.000Z","date":"2018-07-26","kind":"sale","acquired":false,"shares":7937,"price":3.63,"value":28811.31,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $3.52 to $3.81. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2479685,"source":{"system":"sec-edgar","filing":"0000925421-18-000263","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000263/edgar.xml","form_type":"4"}},{"id":3860138,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-27T20:21:45.000Z","date":"2018-07-25","kind":"sale","acquired":false,"shares":12460,"price":3.84,"value":47846.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $3.75 to $3.92. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2487622,"source":{"system":"sec-edgar","filing":"0000925421-18-000263","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000263/edgar.xml","form_type":"4"}},{"id":3861623,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-25T20:35:20.000Z","date":"2018-07-24","kind":"sale","acquired":false,"shares":700,"price":4.11,"value":2877.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $4.04 to $4.22. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2500082,"source":{"system":"sec-edgar","filing":"0000925421-18-000261","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000261/edgar.xml","form_type":"4"}},{"id":3861622,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-25T20:35:20.000Z","date":"2018-07-23","kind":"sale","acquired":false,"shares":30600,"price":4.25,"value":130050.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $4.23 to $4.33. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2500782,"source":{"system":"sec-edgar","filing":"0000925421-18-000261","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000261/edgar.xml","form_type":"4"}},{"id":3865523,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-18T20:17:52.000Z","date":"2018-07-17","kind":"sale","acquired":false,"shares":12500,"price":4.71,"value":58875.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2531382,"source":{"system":"sec-edgar","filing":"0000925421-18-000259","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000259/edgar.xml","form_type":"4"}},{"id":3865522,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-18T20:17:52.000Z","date":"2018-07-16","kind":"sale","acquired":false,"shares":300,"price":5.15,"value":1545.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $5.14 to $5.16. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2543882,"source":{"system":"sec-edgar","filing":"0000925421-18-000259","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000092542118000259/edgar.xml","form_type":"4"}},{"id":3868079,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-07-13T20:02:40.000Z","date":"2018-07-11","kind":"other","acquired":false,"shares":344.9287,"price":940,"value":324232.978,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Exchange Agreement between the Issuer and the Reporting Persons dated July 11, 2018, the remaining shares of the Issuer's Series B Convertible Preferred Stock (the \"Preferred Stock\") were exchanged for shares of the Issuer's common stock, par value $0.0001 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":0,"derivative":{"exercise_price":2.67,"exercise_date":"2017-08-21","expiration_date":"2018-08-15","underlying":"Common Stock, par value $0.0001","underlying_shares":129188},"source":{"system":"sec-edgar","filing":"0001012975-18-000911","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518000911/edgar.xml","form_type":"4"}},{"id":3868078,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2018-07-13T20:02:40.000Z","date":"2018-07-11","kind":"other","acquired":true,"shares":663346,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Exchange Agreement between the Issuer and the Reporting Persons dated July 11, 2018, the remaining shares of the Issuer's Series B Convertible Preferred Stock (the \"Preferred Stock\") were exchanged for shares of the Issuer's common stock, par value $0.0001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Exchange Agreement between the Issuer and the Reporting Persons dated July 11, 2018, the remaining shares of the Issuer's Series B Convertible Preferred Stock (the \"Preferred Stock\") were exchanged for shares of the Issuer's common stock, par value $0.0001 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":6275152,"source":{"system":"sec-edgar","filing":"0001012975-18-000911","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518000911/edgar.xml","form_type":"4"}},{"id":3889163,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2018-06-19T21:03:39.000Z","date":"2018-06-15","kind":"other","acquired":true,"shares":14449,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4410 per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4410 per share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":5611806,"source":{"system":"sec-edgar","filing":"0001012975-18-000853","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518000853/edgar.xml","form_type":"4"}},{"id":3892794,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-15T21:11:31.000Z","date":"2018-06-13","kind":"other","acquired":false,"shares":344.9398,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Issuer's Preferred Stock is convertible at any time at the option of the holder into shares of the Issuer's Common Stock, subject to certain restrictions, at an initial conversion price of $2.67 per share and a stated amount of $1,000 per share."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4785 per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4785 per share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":344.9287,"derivative":{"exercise_price":2.67,"exercise_date":"2017-08-21","expiration_date":"2018-08-15","underlying":"Common Stock, par value $0.0001","underlying_shares":129188},"source":{"system":"sec-edgar","filing":"0001012975-18-000851","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518000851/edgar.xml","form_type":"4"}},{"id":3892793,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2018-06-15T21:11:31.000Z","date":"2018-06-13","kind":"other","acquired":true,"shares":720878,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4785 per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4785 per share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":5597357,"source":{"system":"sec-edgar","filing":"0001012975-18-000851","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518000851/edgar.xml","form_type":"4"}},{"id":3928714,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-05-17T20:07:58.000Z","date":"2018-05-16","kind":"other","acquired":false,"shares":344.9398,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Issuer's Preferred Stock is convertible at any time at the option of the holder into shares of the Issuer's Common Stock, subject to certain restrictions, at an initial conversion price of $2.67 per share and a stated amount of $1,000 per share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4493 per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4493 per share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":689.8685,"derivative":{"exercise_price":2.67,"exercise_date":"2017-08-21","expiration_date":"2018-08-15","underlying":"Common Stock, par value $0.0001","underlying_shares":129188},"source":{"system":"sec-edgar","filing":"0001012975-18-000444","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518000444/edgar.xml","form_type":"4"}},{"id":3928713,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2018-05-17T20:07:58.000Z","date":"2018-05-16","kind":"other","acquired":true,"shares":767728,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4493 per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4493 per share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":4876479,"source":{"system":"sec-edgar","filing":"0001012975-18-000444","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518000444/edgar.xml","form_type":"4"}},{"id":3928712,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2018-05-17T20:07:58.000Z","date":"2018-05-15","kind":"other","acquired":true,"shares":274703,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4553 per share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Series B Convertible Preferred Stock (the \"Preferred Stock\"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\") at the installment conversion price of  $0.4553 per share of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The board of directors of Novartis Bioventures Ltd has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd is an indirectly owned subsidiary of Novartis AG."}],"balance_after":4108751,"source":{"system":"sec-edgar","filing":"0001012975-18-000444","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000101297518000444/edgar.xml","form_type":"4"}},{"id":3935056,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"ten_percent_owner":true}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2018-05-14T20:01:23.000Z","date":"2018-05-11","kind":"sale","acquired":false,"shares":19550,"price":10.06,"value":196673.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.25. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2175314,"source":{"system":"sec-edgar","filing":"0001140361-18-023310","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000114036118023310/form4.xml","form_type":"4"}},{"id":3937307,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"ten_percent_owner":true}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2018-05-11T20:28:15.000Z","date":"2018-05-10","kind":"sale","acquired":false,"shares":22725,"price":10.13,"value":230204.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.34. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2194864,"source":{"system":"sec-edgar","filing":"0001140361-18-023060","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000114036118023060/form4.xml","form_type":"4"}},{"id":3937306,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"ten_percent_owner":true}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2018-05-11T20:28:15.000Z","date":"2018-05-09","kind":"sale","acquired":false,"shares":51230,"price":10.11,"value":517935.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.48. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2217589,"source":{"system":"sec-edgar","filing":"0001140361-18-023060","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000114036118023060/form4.xml","form_type":"4"}},{"id":3941279,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"ten_percent_owner":true}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2018-05-09T20:01:22.000Z","date":"2018-05-08","kind":"sale","acquired":false,"shares":26557,"price":10.03,"value":266366.71,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.12. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2268819,"source":{"system":"sec-edgar","filing":"0001140361-18-022477","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000114036118022477/form4.xml","form_type":"4"}},{"id":3941278,"issuer":{"id":2649,"kind":"organization","name":"Spyre Therapeutics, Inc.","symbol":"SYRE"},"owners":[{"id":148069,"kind":"organization","name":"Novartis Bioventures Ltd","position":1,"cik":"0001297709","reported_name":"Novartis Bioventures Ltd","relationship":{"ten_percent_owner":true}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2018-05-09T20:01:22.000Z","date":"2018-05-07","kind":"sale","acquired":false,"shares":15548,"price":10.11,"value":157190.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $10.00 to $10.33. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities."}],"balance_after":2295376,"source":{"system":"sec-edgar","filing":"0001140361-18-022477","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000114036118022477/form4.xml","form_type":"4"}},{"id":3958741,"issuer":{"id":109857,"kind":"organization","name":"Surface Oncology, Inc.","symbol":"SURF"},"owners":[{"id":160261,"kind":"organization","name":"Novartis Institutes for BioMedical Research, Inc.","position":1,"cik":"0001673852","reported_name":"Novartis Institutes for BioMedical Research, Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2817,"kind":"organization","name":"NOVARTIS AG","position":2,"cik":"0001114448","reported_name":"NOVARTIS AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2018-04-23T20:43:23.000Z","date":"2018-04-23","kind":"exercise","acquired":false,"shares":5214286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The 5,214,286 shares of Series A-1 Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 909,090 shares of the Issuer's Common Stock without payment or further consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The 5,214,286 shares of Series A-1 Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 909,090 shares of the Issuer's Common Stock without payment or further consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Not applicable."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Novartis Institutes for BioMedical Research, Inc. (\"NIBRI\"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":909090},"source":{"system":"sec-edgar","filing":"0001104659-18-025864","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1114448/000110465918025864/a4.xml","form_type":"4"}}],"next_cursor":"2018-04-23T20:43:23.000000Z,3958741"}